contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      viewerIsFollowing
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    ... on Webcast {
      liveTime
      tags {
        viewerIsFollowing
        id
      }
    }
    slug
    ... on CompanyReport {
      tags {
        viewerIsFollowing
        id
      }
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


enzymatica-covid-19-continues-to-subdue-the-cold-abg

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Enzymatica is a life science company that develops and sells medical devices against infectious diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and shorten the duration of the illness. The product has been launched in several markets and the strategy is to expand to more markets through partners. The head office is located in Lund.

Enzymatica

Early signs of recovery for struggling cold remedy marketCold markets continue to be impacted by the pandemic, with increased hand hygiene and social distancing subduing the spread of cold viruses...

Early signs of recovery for struggling cold remedy market Cold markets continue to be impacted by the pandemic, with increased hand hygiene and social distancing subduing the spread of cold viruses. Consequently, Enzymatica’s Q2’21 net sales came in below our estimate (SEK 6m, -50% vs. ABGSCe) in what is a seasonally small quarter. Naturally, profitability was also impacted, with EBIT at SEK -20m (vs. ABGSCe at -12m). While current market conditions are tough, there are positive data points coming out of Australia, which is entering its cold season and is seeing early signs of the season being closer to pre-pandemic levels. As COVID-19 vaccination programmes progress, management anticipates a recovery towards the more important Q4’21. New sales agreement and CEO announced in the quarter Enzymatica announced another partnership in the quarter, when it agreed with STADA to market ColdZyme in Vietnam. In total, the company now has agreements in place for access to around 60 markets, about half of which are launched and the rest expected to launch in ’21-‘22. In addition, it also launched through a digital channel with Amazon (Sweden and UK) in the quarter. It has now been decided that Claus Egstrand, currently COO, will take over as permanent CEO of Enzymatica, starting 1 January 2022 at the latest. Mr Egstrand has been with Enzymatica since 2017 and has previously held senior positions in consumer care divisions at companies such as Merck, Pfizer and Stryker. EV/sales of 20-7x in ‘21e-‘23e for a 25% sales CAGR ’20-‘23e On the back of the report we lower our estimates for H2’21e-H1’22e, reflecting the uncertainty surrounding a recovery in the market for cold remedies. The company completed an equity issue in the quarter, raising SEK 59m. The current cash position is SEK 65m, which management believes will facilitate continued international expansion and cover working capital needs for the coming 12 months.